Overview
Aptus Endosystems is a privately held, well-funded, emerging medical device company that is engaged in the development of next generation minimally invasive endograft devices, delivery systems and fixation technology for the treatment of Abdominal Aortic Aneurysms - the 13th leading cause of death in the United States and the 10th leading cause of death in men over the age of 55. The Company is addressing a potential worldwide market opportunity in excess of $1B.
Background
Aptus Endosystems was co-founded in 2002 by Alan Kaganov, company Chairman, and a partner at the venture capital firm of US Venture Partners, and Lee Bolduc, the company's Vice President of Engineering and Chief Technical Officer; with the mission to develop products that enable safe and durable endovascular repair for a broader base of patients that present with abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA).
Aptus Endosystems is located in a 12,000 sq. ft. facility in Sunnyvale, CA and has completed enrollment in both the feasibility (STAPLE-1) Clinical Trial and pivotal (STAPLE-2) Clinical Trial in the US as part of its commercialization efforts for the Aptus™ Endovascular AAA Repair System. Aptus Endosystems is pursuing next generation designs and technologies applicable to the Thoracic Aortic Aneurysm market.